Reba Harris was the fearless leader of the Gilead House, a 27-bed women’s shelter which offers support services, classes and ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $93.07 which represents a slight increase of $0.15 or 0.16% from the prior close of $92.92. The stock opened at $92.36 and ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.92 which represents a decrease of $-0.12 or -0.13% from the prior close of $93.04. The stock opened at $93.03 and touched a low of ...

Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...